BSD Medical Hyperthermia Systems Featured at the Society for Thermal Medicine Annual Conference

  BSD Medical Hyperthermia Systems Featured at the Society for Thermal
  Medicine Annual Conference

  Conference highlighted potential use of thermal therapy and ablation as a
 trigger for an anti-cancer immune response, which could be a key approach in
                            future cancer therapy

Business Wire

SALT LAKE CITY -- June 5, 2014

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, today announced BSD hyperthermia systems were featured in multiple
presentations at the 31^st Annual Conference of the Society for Thermal
Medicine (STM). There were many presentations during the conference regarding
innovative uses of thermal therapy in the treatment of patients with a variety
of cancers.

A keynote lecture by Gosse Adema Ph.D., Department of Tumor Immunology,
Radboud University, The Netherlands titled, “Local Tumor Ablation plus Immune
Stimulation: Towards in situ Cancer Vaccines,” addressed the use of thermal
therapy and ablation therapy as a trigger for an anti-cancer immune response.
Professor Adema reported that thermal therapy can trigger the immune response
and stimulate the creation of dendritic cells, which can be used to destroy
cancer cells. Professor Adema concluded that the use of thermal and ablation
therapy to trigger an anti-cancer immune response could be a key approach in
future cancer therapy.

Douglas Kelly, Michael Payne, Edwin Watts, James Flynn, David Simon, Tyler
Gutschenritter, and Matt Weaver, Cancer Treatment Centers of America, Tulsa,
gave a presentation on the use of regional hyperthermia to treat cervical
carcinoma. They reported on the use of the BSD-2000 Hyperthermia System
(BSD-2000) to treat 15 cervical cancer patients. Of the evaluable patients,
the overall responses (complete response plus partial response) included 4/4
(100%) for newly diagnosed patients and 6/9 (67%) for recurrent patients. The
researchers stated, "The authors have found hyperthermia to be a useful
addition to the radiation management of cervical carcinoma."

Payne, Kelly, Simon, Gutschenritter, Flynn, Weaver and Oneita Taylor, Cancer
Treatment Centers of America, Tulsa, presented a poster on the use of the
BSD-2000 to treat 10 patients with unresectable, locally advanced, pelvic
tumors. The researchers reported, "In sum, the results of the initial
evaluation of this study are encouraging and provide motivation for continual
inquiry into the utilization of hyperthermia as an adjuvant standard of care
in patients with pelvic tumors."

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE Marking approval is also recognized in many
countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William Barth, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930
 
Press spacebar to pause and continue. Press esc to stop.